Which companies overlap with El Kendi Pharmaceuticals Manufacturing Company's portfolio?

Top competitors by shared drug class: Biotech Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Sun Yat-sen University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/el-kendi-pharmaceuticals-manufacturing-company.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

El Kendi Pharmaceuticals Manufacturing Company — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

El Kendi Pharmaceuticals Manufacturing Company pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Nimotuzumab ( h-R3)	Nimotuzumab ( h-R3)	phase 3	EGFR inhibitor monoclonal antibody	EGFR (Epidermal Growth Factor Receptor)	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Biotech Pharmaceutical Co., Ltd. · 1 shared drug class
Shanghai Miracogen Inc. · 1 shared drug class
Sun Yat-sen University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for El Kendi Pharmaceuticals Manufacturing Company:

Cite this brief

Drug Landscape (2026). El Kendi Pharmaceuticals Manufacturing Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/el-kendi-pharmaceuticals-manufacturing-company. Accessed 2026-05-17.